Santhera’s US partner launches Duchenne muscular dystrophy treatment

• AGAMREE is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older
• This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera
• AGAMREE is the first DMD treatment approved across the U.S., EU and UK

“Congratulations to our partner Catalyst on the launch of AGAMREE in the United States. Following the first global market introduction of this novel product in Germany in January, this launch represents an important next step in making AGAMREE available to as many patients with DMD as soon as possible,” said Dario Eklund, CEO of Santhera.

The launch of AGAMREE in the U.S. follows the approval of the product by the U.S. Food and Drug Administration (FDA) on October 26, 2023, based on data from the pivotal VISION-DMD study, recently published in Neurology, and supplemented with safety information collected from three open-label studies, including extension studies.

According to the license agreement between the companies, first announced in June 2023, Catalyst holds an exclusive North American license to commercialize AGAMREE for DMD and all potential future indications. Under the agreement, Catalyst will pay Santhera sales-based milestones of up to USD 105 million as well as up to low-teen percentage royalties and will assume Santhera's corresponding third-party royalty obligations on AGAMREE sales in all indications in North America.

References:
[1]   Dang UJ et al. (2024) Neurology 2024;102:e208112. doi.org/10.1212/WNL.0000000000208112. Link.
[2]    Guglieri M et al (2022). JAMA Neurol. 2022;79(10):1005-1014. doi:10.1001/jamaneurol.2022.2480. Link.
[3]    Liu X et al (2020). Proc Natl Acad Sci USA 117:24285-24293
[4]    Heier CR et al (2019). Life Science Alliance DOI: 10.26508
[5]    Ward et al., WMS 2022, FP.27 - Poster 71. Link.
[6]   Hasham et al., MDA 2022 Poster presentation. Link.